UPB (Upstream Bio) Other Current Liabilities : $0.88 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Other Current Liabilities?

Upstream Bio's other current liabilities for the quarter that ended in Mar. 2025 was $0.88 Mil.

Upstream Bio's quarterly other current liabilities increased from Sep. 2024 ($2.12 Mil) to Dec. 2024 ($2.70 Mil) but then declined from Dec. 2024 ($2.70 Mil) to Mar. 2025 ($0.88 Mil).

Upstream Bio's annual other current liabilities increased from Dec. 2022 ($0.89 Mil) to Dec. 2023 ($2.17 Mil) and increased from Dec. 2023 ($2.17 Mil) to Dec. 2024 ($2.70 Mil).

Upstream Bio Other Current Liabilities Historical Data

The historical data trend for Upstream Bio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Other Current Liabilities Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Other Current Liabilities

0.89

2.17

2.70

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Current Liabilities	Get a 7-Day Free Trial			-	1.62	2.12	2.70	0.88

Upstream Bio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Upstream Bio Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.